Skip to main content

IPO Chilli Ratings

IPO Chilli Ratings
Click to understand how it works

Featured

Singapore Institute of Advanced Medicine Holdings Ltd

Singapore Institute of Advanced Medicine Holdings Ltd ("Sam" or the "Company") is offering 114m new shares comprising 4.415m Public Offer Shares and 109.585m Placement Shares at $0.23 each for a listing on Catalist.  The Company aims to raise $26.2m and the majority of the proceeds will be used to repay debt and the balance for working capital. The market cap based on the IPO price is $231.8m and the offer will close on 14 Feb at 12 noon and starts trading on 16 Feb 2024 at 9am.   Principal Business SAM is a healthcare service provider using advanced technology for early and accurate diagnosis to detect and treat cancer, neurodegenerative and cardiovascular diseases.  SAM has strategic collaborations with public and private institutions for research and clinical work.  SAM's goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer and is one of the first to adopt proto beam therapy treatment in Singapore. Fi

Reyphon Agriceutical Limited


(IPO booth at Raffles Place on a rainy day)

Reyphon Agriceutical Limited is a manufacturer of agriceutical products and its principal products are gibberellic acids and plant antibiotic. The prospectus is here.

Public offer: 2m shares at 39 cents
Placement offer: 76.6m shares
Closing date: 30 July 2007
Manager: Philip Capital



This is an interesting company amidst the hoo-har about food safety in China. China passes its first draft on Food Safety today. The tighter regulation for food safety will actually mean good news to ISO-certified agriceutical companies like Reyphon and i believed Reyphon is 'first-of-its-kind' listing on SGX. I cannot recall a similar companies in this field. The listing of this company also means a windfall for Sinomen as it holds 52% of Reyphon post-IPO.

The growth of this Company has been very impressive and it is likely that this growth can be sustained with the increased in production facilities post its listing. EPS for 2006 based on post ipo share of 313.8m shares is Singapore 2.694 cents. Assuming its profit grow by another 50% in 2007, the EPS will be 4.041 cents. Based on valuation matrix of 15-20x PE, the fair value price will range between 61 cents and 81 cents, a significant upside from IPO price and under current sentiments, it will even exceed my 81 cents fair value if investors priced towards 2008 estimates.

Just hoot it although i must say that it will be extremely tough to get it (what'z new ah?)

Comments

Mr. IPO said…
After doing a more detailed analysis, peers will include China XLX and this China XLX is trading at high PE mulitple!
Anonymous said…
hi..whats the net effect on Sinomem's share price if, say, Reyphon closes at 80ct?
Anonymous said…
hi.i thought Sinomem owns 68% of Reyphon...how did you get your figure pls?...

tx!
2Y Capital said…
68% is before the IPO. Post IPO (i.e including the new shares issuance) the % drop to 52%. It is on page 73 of the prospectus.

It is always difficult to 'quantify' the impact of Reyphon on Sinomen but it will be a positive one. Somewhat like the impact which Swiber has on Swissco.
Anonymous said…
with 29% capacity expansion ready only during end of FY07
and around 98% utilization rate at the moment... dont think that profit can grow by 50%, at best 30%